The AAPS Journal

, Volume 13, Issue 3, pp 438–444 | Cite as

Vaccinomics: Current Findings, Challenges and Novel Approaches for Vaccine Development

Mini-Review Theme: Emerging Concepts for Vaccine Development and Vaccination


Recent years have witnessed a growing interest in a field of vaccinology that we have named vaccinomics. The overall idea behind vaccinomics is to identify genetic and other mechanisms and pathways that determine immune responses, and thereby provide new candidate vaccine approaches. Considerable data show that host genetic polymorphisms act as important determinants of innate and adaptive immunity to vaccines. This review highlights examples of the role of immunogenetics and immunogenomics in understanding immune responses to vaccination, which are highly variable across the population. The influence of HLA genes, non-HLA, and innate genes in inter-individual variations in immune responses to viral vaccines are examined using population-based gene/SNP association studies. The ability to understand relationships between immune response gene variants and vaccine-specific immunity may assist in designing new vaccines. At the same time, application of state-of-the-art next-generation sequencing technology (and bioinformatics) is desired to provide new genetic information and its relationship to the immune response.

Key words

genetic association HLA immunogenetics polymorphisms SNPs vaccines vaccinomics 



We thank our subjects and their parents who participated in our studies and the Mayo Clinic Vaccine Research Group staff. We thank Richard B. Kennedy for help in preparing the figure. This work was supported by NIH grants AI 48793, AI 33144 and 1 UL1 RR024150-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health, and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.


Dr. Poland is the chair of a Safety Evaluation Committee for an investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on new vaccine development to Merck & Co., Inc., Avianax, Theraclone Sciences (formally Spaltudaq Corporation), MedImmune LLC, Liquidia Technologies, Inc., Emergent BioSolutions, Novavax, Dynavax, EMD Serono, Inc., Novartis Vaccines and Therapeutics and PAXVAX, Inc.


  1. 1.
    Poland GA. Pharmacology, vaccinomics, and the second golden age of vaccinology. Clin Pharmacol Ther. 2007;82(6):623–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther. 2007;82(6):653–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther. 2008;8(11):1659–67.PubMedCrossRefGoogle Scholar
  4. 4.
    Marchant A, Pihlgren M, Goetghebuer T, Weiss HA, Ota MO, Schlegel-Hauter SE, et al. Predominant influence of environmental determinants on the persistence and avidity maturation of antibody responses to vaccines in infants. J Infect Dis. 2006;193(11):1598–605.PubMedCrossRefGoogle Scholar
  5. 5.
    Jacobson RM, Ovsyannikova IG, Targonski PV, Poland GA. Studies of twins in vaccinology. Vaccine. 2007;25(16):3160–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV. Twin studies of immunogenicity—determining the genetic contribution to vaccine failure. Vaccine. 2001;19:2434–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Newport MJ, Goetghebuer T, Weiss HA. The MRC Gambia Twin Study Group, Whittle H, Siegrist C-A, et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 2004;5(2):122–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Poland GA, Jacobson RM, Ovsyannikova IG. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine and consumer culture and vaccinomics. Vaccine. 2009;27(25–26):3240–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics. 2009;10(5):837–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol. 1997;26(3):503–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Gelder CM, Lambkin R, Hart KW, Fleming D, Williams OM, Bunce M, et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis. 2002;185:114–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz SV, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine. 2004;22:1914–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine. 2008;26S:D35–40.CrossRefGoogle Scholar
  14. 14.
    Jacobson RM, Poland GA, Vierkant RA, Pankratz VS, Schaid DJ, Jacobsen SJ, et al. The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum Immunol. 2003;64(1):103–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis. 2006;193(5):655–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Ovsyannikova IG, Jacobson RM, Vierkant RA, O'Byrne MM, Poland GA. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine. 2009;27(49):6926–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol. 2004;65:1506–15.PubMedCrossRefGoogle Scholar
  18. 18.
    Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics. 2008;121:e1091–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ovsyannikova IG, Ryan JE, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine. 2009;27:3359–66.PubMedCrossRefGoogle Scholar
  20. 20.
    Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. PLoS ONE. 2010;5(7):e11806.PubMedCrossRefGoogle Scholar
  22. 22.
    Poland GA, Ovsyannikova IG, Jacobson RM. Vaccine immunogenetics: bedside to bench to population. Vaccine. 2008;26:6183–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Poland GA, Ovsyannikova IG, Jacobson RM. Genetics and immune response to vaccines. In: Kaslow RA, McNicholl JM, Hill AVS, editors. Genetic susceptibility to infectious diseases. New York, New York: Oxford University Press; 2008. p. 414–29.Google Scholar
  24. 24.
    Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet. 2002;360(9338):991–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Dhiman N, Haralambieva IH, Kennedy RB, Vierkant RA, O'Byrne MM, Ovsyannikova IG, et al. Assesment of SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccination. Immunogenetics. 2010;62(4):197–210.PubMedCrossRefGoogle Scholar
  26. 26.
    Jin P, Wang E. Polymorphism in clinical immunology—from HLA typing to immunogenetic profiling. J Transl Med. 2003;1(1):8.PubMedCrossRefGoogle Scholar
  27. 27.
    Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK. Development of smallpox vaccine candidates with integrated IL-15 that demonstrate superior immunogenicity, efficacy and safety in mice. J Virol. 2007;81(16):8774–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Keen LJ. The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol. 2002;10(2–3):143–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Ovsyannikova IG, Haralambieva IH, Dhiman N, O'Byrne MM, Pankratz VS, Jacobson RM, et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis. 2010;201(2):207–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Sawyer SL, Wu LI, Akey JM, Emerman M, Malik HS. High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr Biol. 2006;16(1):95–100.PubMedCrossRefGoogle Scholar
  31. 31.
    van Manen D, Rits MA, Beugeling C, van Dort K, Schuitemaker H, Kootstra NA. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 2008;4(2):e18.PubMedCrossRefGoogle Scholar
  32. 32.
    Ovsyannikova IG, Dhiman N, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, et al. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet. 2010;127:207–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol. 2005;42(8):859–67.PubMedCrossRefGoogle Scholar
  34. 34.
    Javanbakht H, An P, Gold B, Petersen DC, O'Huigin C, Nelson GW, et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology. 2006;354(1):15–27.PubMedCrossRefGoogle Scholar
  35. 35.
    Goldschmidt V, Bleiber G, May M, Martinez R, Ortiz M, Telenti A. Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology. 2006;3:54.PubMedCrossRefGoogle Scholar
  36. 36.
    Haralambieva IH, Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, et al. 2′-5′-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol. 2010;71(4):383–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628–32.PubMedCrossRefGoogle Scholar
  38. 38.
    Lau YF, Tang LH, Ooi EE. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine. 2009;27(9):1354–64.PubMedCrossRefGoogle Scholar
  39. 39.
    Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004;24(6):693–701.PubMedCrossRefGoogle Scholar
  40. 40.
    Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Klinman D, Berzofsky JA. Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J Immunol. 2006;177(9):6336–43.PubMedGoogle Scholar
  41. 41.
    Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;118(5):1590–605.PubMedCrossRefGoogle Scholar
  42. 42.
    Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Genetics. 2005;6:95–108.PubMedGoogle Scholar
  43. 43.
    Igl BW, Konig IR, Ziegler A. What do we mean by ‘replication’ and ‘validation’ in genome-wide association studies? Hum Hered. 2009;67(1):66–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al. Replicating genotype-phenotype associations. Nature. 2007;447(7145):655–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116–25.PubMedCrossRefGoogle Scholar
  46. 46.
    Dhiman N, Smith DI, Poland GA. Next-generation sequencing: a transformative tool for vaccinology. Expert Rev Vaccine. 2009;8(8):963–7.CrossRefGoogle Scholar
  47. 47.
    Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. HLA supertypes and immune responses to measles–mumps–rubella viral vaccine: findings and implications for vaccine design. Vaccine. 2007;25(16):3090–100.PubMedCrossRefGoogle Scholar
  48. 48.
    Ovsyannikova IG, Vierkant RA, Pankratz VS, O'Byrne MM, Jacobson RM, Poland GA. HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine. 2009;27:3349–58.PubMedCrossRefGoogle Scholar
  49. 49.
    Sinha P, Snyder JA, Kim EY, Moudgil KD. The major histocompatibility complex haplotypes dictate and the background genes fine-tune the dominant versus the cryptic response profile of a T-cell determinant within a native antigen: relevance to disease susceptibility and vaccination. Scand J Immunol. 2007;65(2):158–65.PubMedCrossRefGoogle Scholar
  50. 50.
    Halassy B, Mateljak S, Bouche FB, Putz MM, Muller CP, Frkanec R, et al. Immunogenicity of peptides of measles virus origin and influence of adjuvants. Vaccine. 2006;24(2):185–94.PubMedCrossRefGoogle Scholar
  51. 51.
    Putz MM, Ammerlaan W, Schneider F, Jung G, Muller CP. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. Vaccine. 2004;22(31–32):4173–82.PubMedCrossRefGoogle Scholar
  52. 52.
    Pasquetto V, Bui HH, Giannino R, Mirza F, Sidney J, Oseroff C, et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol. 2005;175(8):5504–15.PubMedGoogle Scholar
  53. 53.
    Spielberg SP. Therapeutics and toxicology. Curr Opin Pediatr. 1998;10:201–2.PubMedCrossRefGoogle Scholar
  54. 54.
    Vandenbroeck K, Goris A. Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sci. 2003;24(6):284–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Kaslow RA, McNicholl JM, Hill AVS. Genetic susceptibility to infectious diseases. New York: Oxford University Press; 2008.Google Scholar
  56. 56.
    Johnson KL, Ovsyannikova IG, Mason CJ, Bergen III HR, Poland GA. Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine. 2009;28(1):38–47.PubMedCrossRefGoogle Scholar
  57. 57.
    Johnson KL, Ovsyannikova IG, Poland G, Muddiman DC. Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry. J Proteome Res. 2005;4:2243–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Ovsyannikova IG, Johnson KL, Naylor S, Muddiman DC, Poland GA. Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood. Virology. 2003;312(2):495–506.PubMedCrossRefGoogle Scholar
  59. 59.
    Ovsyannikova IG, Johnson KL, Muddiman DC, Vierkant RA, Poland GA. Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides. J Virol. 2004;78(1):42–51.PubMedCrossRefGoogle Scholar
  60. 60.
    Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004;39(4):978–88.PubMedCrossRefGoogle Scholar
  61. 61.
    Kim M-J, Nafziger AN, Harro CD, Keyserling HL, Ramsey KM, Drusano GL, et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine. 2003;21(11–12):1174–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Lee HG, Lim J-S, Lee K-Y, Choi Y-K, Choe I-S, Chung T-W, et al. Peptide-specific CTL induction in HBV-seropositive PBMC by stimulation with peptides in vitro: novel epitopes identified from chronic carriers. Virus Res. 1997;50:185–94.PubMedCrossRefGoogle Scholar
  63. 63.
    Dhiman N, Cunningham JM, Jacobson RM, Vierkant RA, Wu Y, Ovsyannikova IG, et al. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J Allergy Clin Immunol. 2007;120(3):666–72.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2011

Authors and Affiliations

  • Inna G. Ovsyannikova
    • 1
    • 2
    • 3
  • Gregory A. Poland
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Vaccine Research GroupMayo ClinicRochesterUSA
  2. 2.Program in Translational Immunovirology and BiodefenseRochesterUSA
  3. 3.Department of MedicineMayo ClinicRochesterUSA
  4. 4.Department of Pediatric and Adolescent MedicineMayo ClinicRochesterUSA
  5. 5.Mayo ClinicRochesterUSA

Personalised recommendations